Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough

PHASE3CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

November 9, 2016

Primary Completion Date

March 6, 2018

Study Completion Date

July 31, 2018

Conditions
Cough
Interventions
DRUG

Levopront® syrup 30 mg/5 ml

The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).

DRUG

Libexin®

The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.

Trial Locations (8)

121374

"State Public Healthcare Institution of Moscow City Clinical Hospital # 71 of Moscow Healthcare Department", Moscow

127473

"The Laboratory of Pulmonology, State Budgetary Educational Institution of Higher Professional Education Moscow State Medical-Stomatological University n.a. A.I. Evdokimov under Ministry of Health of the Russian Federation (Clinical base of state budget", Moscow

150003

"State Autonomous Healthcare Institution of Yaroslavl Region Clinical Hospital of Emergency care n.a. N.V. Solovyev", Yaroslavl

196084

"Institute of Medical Research LLC", Saint Petersburg

198510

"Saint-Petersburg State Healthcare Institution Nikolaevskaya Hospital", Saint Petersburg

214016

"LLC Treatment-and-prophylactic institution on the Smolensk clinic", Smolensk

390026

"State Budgetary Educational Institution of Higher Professional Education Ryazan' State Medical University n.a. academician I.P. Pavlov under Ministry of Health of the Russian Federation", Ryazan

410053

"State Healthcare Institution Regional Clinical Hospital", Saratov

All Listed Sponsors
lead

Dompé Farmaceutici S.p.A

INDUSTRY

NCT03837938 - Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough | Biotech Hunter | Biotech Hunter